MedTrace Logo

Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma

NCT01570049 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2012-08-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether bendamustine HCl for injection is safe and effective in the treatment of Rituximab refractory or relapsed B-cell indolent lymphoma.

Conditions

  • Non-Hodgkin Lymphoma by Clinical Course

Interventions

DRUG

Bendamustine

for injection

Sponsors & Collaborators

  • Shandong Lanjin Pharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Huaqing Wang, master · Tianjin Medical University Cancer Institute and Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-09-30
Completion
2012-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01570049 on ClinicalTrials.gov